Cargando…

EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?

BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing is restricted to several limitations. In this study, we examined the relationship between EGFR mutation status and clinicoradiological characteristics in a Chinese cohort of patients. MATERIALS AND METHODS: The data of patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Xiaoyi, Gu, Xiaolong, Lu, Yingru, Zhou, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173510/ https://www.ncbi.nlm.nih.gov/pubmed/30323660 http://dx.doi.org/10.2147/CMAR.S174623

Ejemplares similares

EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma
por: Memon, Aadil Ahmed, et al.
Publicado: (2017)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
por: Ohmori, Tohru, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status
por: Pak, Min Gyoung, et al.
Publicado: (2015)

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)

High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes
por: Li, Yan, et al.
Publicado: (2020)

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
por: Li, Kaidi, et al.
Publicado: (2017)

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
por: Lin, Liping, et al.
Publicado: (2018)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
por: Zhang, Xiaozhu, et al.
Publicado: (2008)

Erratum to NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
Publicado: (2022)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Gu, Yangchun, et al.
Publicado: (2021)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
por: Phan, Thang Thanh, et al.
Publicado: (2019)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
por: Wu, Jing-Xun, et al.
Publicado: (2018)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study
por: Liu, Yuting, et al.
Publicado: (2021)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2021)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
por: ZHOU, BO, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ksq42605ecf811gt8rtm1slvv1